BACKGROUND AND PURPOSE: The relationship between lesion formation and brain atrophy development in the early phase of multiple sclerosis is unclear. We investigated the association between new lesion accumulation and brain atrophy progression in patients with clinically isolated syndrome over 48 months. MATERIALS AND METHODS: Patients with clinically isolated syndrome (n = 210) were evaluated with 1.5T MR imaging at baseline and at 6, 12, 24, 36, and 48 months as part of a multicenter observational study of early administration of intramuscular interferon β-1a. Mixed-effect model analyses, adjusted for age, sex, and treatment status, investigated the association between accumulation of contrast-enhancing and T2 lesions and brain-volume percent changes in a 48-month period. RESULTS: In patients with clinically isolated syndrome, the average whole-brain volume decreased 2.5%, the mean lateral ventricle volume increased 16.9%, and a mean of 7.7 new/enlarging T2 lesions accumulated over the follow-up period. Patients with clinically isolated syndrome who showed greater percentages of change in whole-brain, white and gray matter, cortical, and lateral ventricle volumes over the follow-up period had more severe lesion outcomes at baseline (all P < .007). There were significant associations between decreased individual brain-volume measures at baseline and greater percentages of change during follow-up (P < .05). We found a significant association between the total cumulative number of new/enlarging T2 lesions and the evolution of whole-brain (P < .001), lateral ventricle (P = .007), gray matter and thalamic (P = .013), subcortical deep gray matter (P = .015), and cortical (P = .036) volumes over the follow-up period. CONCLUSIONS: Lesion accumulation and brain-volume changes occur simultaneously in the early phase of clinically isolated syndrome. More severe lesion and brain-volume outcomes at baseline were associated with greater development of brain atrophy over the follow-up period in patients with clinically isolated syndrome.

Department of Neurology and Center of Clinical Neuroscience

Department of Radiology Charles University Prague 1st Faculty of Medicine and General University Hospital Prague Czech Republic

From the Buffalo Neuroimaging Analysis Center

From the Buffalo Neuroimaging Analysis Center Department of Neurology University at Buffalo SUNY Buffalo New York

From the Buffalo Neuroimaging Analysis Center Don Gnocchi Foundation Milan Italy

See more in PubMed

Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129:606–16 PubMed

Zivadinov R, Bakshi R. Role of MRI in multiple sclerosis II: brain and spinal cord atrophy. Front Biosci 2004;9:647–64 PubMed

Miller DH, Barkhof F, Frank JA, et al. . Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125:1676–95 PubMed

Geurts JJ, Stys PK, Minagar A, et al. . Gray matter pathology in (chronic) MS: modern views on an early observation. J Neurol Sci 2009;282:12–20 PubMed

Zivadinov R, Havrdová E, Bergsland N, et al. . Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 2013;268:831–41 PubMed

Calabrese M, Rinaldi F, Mattisi I, et al. . The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011;77:257–63 PubMed

Dalton CM, Chard DT, Davies GR, et al. . Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004;127:1101–07 PubMed

Raz E, Cercignani M, Sbardella E, et al. . Gray- and white-matter changes 1 year after first clinical episode of multiple sclerosis: MR imaging. Radiology 2010;257:448–54 PubMed

Fisniku LK, Chard DT, Jackson JS, et al. . Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008;64:247–54 PubMed

Zivadinov R, Bergsland N, Dolezal O, et al. . Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. AJNR Am J Neuroradiol 2013;34:1931–39 PubMed PMC

Fisher E, Lee JC, Nakamura K, et al. . Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64:255–65 PubMed

Cappellani R, Bergsland N, Weinstock-Guttman B, et al. . Subcortical deep gray matter pathology in patients with multiple sclerosis is associated with white matter lesion burden and atrophy but not with cortical atrophy: a diffusion tensor MRI study. AJNR Am J Neuroradiol 2014;35:912–19 PubMed PMC

Roosendaal SD, Bendfeldt K, Vrenken H, et al. . Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler 2011;17:1098–106 PubMed

Kalincik T, Vaneckova M, Tyblova M, et al. . Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. PLoS ONE 2012;7:e50101. PubMed PMC

Uher T, Benedict RH, Horakova D, et al. . Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. J Neurol Sci 2014;347:229–34 PubMed

Uher T, Blahova-Dusankova J, Horakova D, et al. . Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. J Neurol 2014;261:1735–44 PubMed

Uher T, Horakova D, Bergsland N, et al. . MRI correlates of disability progression in patients with CIS over 48 months. Neuroimage Clin 2014;6:312–19 PubMed PMC

Zivadinov R, Heininen-Brown M, Schirda CV, et al. . Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 2012;59:331–39 PubMed

Smith SM, Zhang Y, Jenkinson M, et al. . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–89 PubMed

Patenaude B, Smith SM, Kennedy DN, et al. . A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011;56:907–22 PubMed PMC

Smith SM, De Stefano N, Jenkinson M, et al. . Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001;25:466–75 PubMed

Dwyer MG, Bergsland N, Zivadinov R. Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model. Neuroimage 2014;90:207–17 PubMed

Benjamini Y, Drai D, Elmer G, et al. . Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001;125:279–84 PubMed

Calabrese M, Atzori M, Bernardi V, et al. . Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol 2007;254:1212–20 PubMed

Comi G, Martinelli V, Rodegher M, et al. . Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler 2013;19:1074–83 PubMed

Zivadinov R, Zorzon M. Is gadolinium enhancement predictive of the development of brain atrophy in multiple sclerosis? A review of the literature. J Neuroimaging 2002;12:302–09 PubMed

Zivadinov R, Bagnato F, Nasuelli D, et al. . Short-term brain atrophy changes in relapsing-remitting multiple sclerosis. J Neurol Sci 2004;223:185–93 PubMed

Rashid W, Davies GR, Chard DT, et al. . Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study. Mult Scler 2007;13:178–85 PubMed

Inglese M, Mancardi GL, Pagani E, et al. . Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry 2004;75:643–44 PubMed PMC

Paolillo A, Piattella MC, Pantano P, et al. . The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J Neurol 2004;251:432–39 PubMed

De Stefano N, Giorgio A, Battaglini M, et al. . Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010;74:1868–76 PubMed

Rojas JI, Patrucco L, Míguez J, et al. . Brain atrophy in radiologically isolated syndromes. J Neuroimaging 2015;25:68–71 PubMed

Dalton CM, Brex PA, Jenkins R, et al. . Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:141–47 PubMed PMC

Magnano C, Schirda C, Weinstock-Guttman B, et al. . Cine cerebrospinal fluid imaging in multiple sclerosis. J Magn Reson Imaging 2012;36:825–34 PubMed

Lucchinetti CF, Popescu BF, Bunyan RF, et al. . Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365:2188–97 PubMed PMC

Calabrese M, Rocca MA, Atzori M, et al. . Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology 2009;72:1330–36 PubMed

Bø L, Vedeler CA, Nyland H, et al. . Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003;9:323–31 PubMed

van Horssen J, Brink BP, de Vries HE, et al. . The blood-brain barrier in cortical multiple sclerosis lesions. J Neuropathol Exp Neurol 2007;66:321–28 PubMed

Geurts JJ, Pouwels PJ, Uitdehaag BM, et al. . Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 2005;236:254–60 PubMed

Fox RJ, Fisher E, Tkach J, et al. . Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications. Mult Scler 2005;11:140–45 PubMed

Hardmeier M, Wagenpfeil S, Freitag P, et al. . Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 2005;64:236–40 PubMed

Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, et al. . Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler 2013;19:1175–81 PubMed

Zivadinov R, Reder AT, Filippi M, et al. . Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008;71:136–44 PubMed

Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis